SELLAS Life Sciences Group Inc buy Maxi_Scalibusa
Start price
23.01.21
/
50%
€4.85
Target price
23.01.22
€50.00
Performance (%)
-9.65%
End price
24.01.22
€4.38
Summary
This prediction ended on 24.01.22 with a price of €4.38. With a performance of -9.65%, the BUY prediction by Maxi_Scalibusa finished with a loss. Maxi_Scalibusa has 50% into this predictionSELLAS Life Sciences is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, is a cancer immunotherapy being developed for the treatment of acute myeloid leukemia (AML) and ovarian cancer. SELLAS Life Sciences is listed on the NASDAQ stock exchange under the symbol RXII.
AI-generated
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| SELLAS Life Sciences Group Inc | 6.250% | 6.250% | 694.964% | 684.801% |
| iShares Core DAX® | 0.437% | 5.897% | 8.047% | 65.579% |
| iShares Nasdaq 100 | 1.057% | 0.920% | 28.466% | 90.185% |
| iShares Nikkei 225® | 1.769% | 1.228% | 47.574% | 84.991% |
| iShares S&P 500 | 0.368% | 1.920% | 23.200% | 70.760% |
Comments by Maxi_Scalibusa for this prediction
In the thread SELLAS Life Sciences Group Inc diskutieren
In the thread Trading SELLAS Life Sciences Group Inc
Die von Maxi_Scalibusa gewählte maximale Laufzeit wurde überschritten